Tamar Securities LLC Buys 1,354 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tamar Securities LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,228 shares of the biopharmaceutical company's stock after buying an additional 1,354 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 2.5% of Tamar Securities LLC's holdings, making the stock its 19th largest position. Tamar Securities LLC's holdings in Regeneron Pharmaceuticals were worth $12,496,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $31,000. Sutton Wealth Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company's stock valued at $39,000 after acquiring an additional 13 shares during the last quarter. Finally, Bruce G. Allen Investments LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $40,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $5.68 during midday trading on Friday, hitting $942.70. 354,446 shares of the company were exchanged, compared to its average volume of 408,818. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The firm has a market cap of $103.47 billion, a P/E ratio of 27.13, a PEG ratio of 2.74 and a beta of 0.11. Regeneron Pharmaceuticals, Inc. has a 52 week low of $684.80 and a 52 week high of $998.33. The firm has a 50 day simple moving average of $959.92 and a 200-day simple moving average of $885.29.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. Regeneron Pharmaceuticals's revenue was up .6% on a year-over-year basis. During the same quarter last year, the company earned $10.96 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 38.18 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joseph L. Goldstein sold 2,707 shares of Regeneron Pharmaceuticals stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $950.00, for a total value of $2,571,650.00. Following the completion of the transaction, the director now owns 6,382 shares of the company's stock, valued at approximately $6,062,900. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock worth $13,124,641 in the last 90 days. 8.83% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on REGN shares. Barclays raised their target price on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the company an "overweight" rating in a report on Tuesday, January 23rd. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $850.00 to $925.00 and gave the company a "neutral" rating in a report on Tuesday, February 6th. Truist Financial reaffirmed a "buy" rating and issued a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday. StockNews.com lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Friday, January 5th. Finally, Morgan Stanley raised their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an "overweight" rating in a report on Wednesday, March 13th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $968.43.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.